Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China
Open Access
- 19 June 2025
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (7) , 3597-3607
Abstract
Hemophagocytic lymphohistiocytosis (HLH) has been described as a threshold disease depending on triggering factors and the residual cytotoxic capacity of NK cells. This study aimed to investigate the clinical characteristics of Epstein–Barr virus (EBV)-triggered primary HLH and the prognostic value of EBV-DNA load in EBV-triggered primary HLH cases. We retrospectively analyzed the clinical data of 95 patients with primary HLH treated between January 2013 and January 2024. Based on the peripheral blood EBV status at initial diagnosis, 57 patients were categorized into the EBV-triggered primary HLH group and 38 patients into the non-EBV-triggered primary HLH group. Clinical and functional characteristics, response to treatment, and prognosis were compared between the two groups. Among patients with EBV-triggered primary HLH, the proportion of patients with familial HLH type 2 (FHL2) was significantly lower (P = 0.011), whereas the proportion of patients with X-linked lymphoproliferative disorder (XLP) was higher (P = 0.037). Functional assays showed that in primary HLH patients with gene defects in cytotoxic degranulation, the proportion of EBV-triggered primary HLH patients with reduced NK cell activity and degranulation function was significantly higher (P = 0.026 and P = 0.030). Importantly, multivariate Cox regression analysis identified EBV-DNA > 10,000 copies/mL as an independent risk factor affecting the prognosis of patients with EBV-triggered primary HLH, particularly in non-FHL cases (P = 0.045). EBV-triggered primary HLH is more prevalent in patients with XLP but less frequent in FHL2 patients. High EBV-DNA load is an adverse prognostic factor in EBV-triggered primary HLH patients.Keywords
Funding Information
- National Natural Science Foundation of China (82370185)
This publication has 36 references indexed in Scilit:
- Spectrum of neuroradiological manifestations in primary hemophagocytic lymphohistiocytosis: a comparative study of EBV-induced versus non-EBV-induced forms in 75 genetically confirmed pediatric casesEuropean Radiology, 2023
- The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic LymphohistiocytosisJournal of Clinical Immunology, 2023
- Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisAnnals of Hematology, 2022
- Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infectionInternational Immunopharmacology, 2021
- Clinical and genetic features of Epstein‐Barr virus‐triggered late‐onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees studyClinical and Translational Medicine, 2021
- Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosisEuropean Journal of Immunology, 2020
- Hemophagocytic syndromes — An updateBlood Reviews, 2014
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabPediatric Blood & Cancer, 2012
- Clinical significance of clonality and Epstein‐Barr virus infection in adult patients with hemophagocytic lymphohistiocytosisAmerican Journal of Hematology, 2010
- Late‐onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutationsAmerican Journal of Hematology, 2007